<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03769116</url>
  </required_header>
  <id_info>
    <org_study_id>SRP-9001-102</org_study_id>
    <nct_id>NCT03769116</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-blind, Placebo-controlled Study of SRP-9001 for Duchenne Muscular Dystrophy (DMD)</brief_title>
  <official_title>A 48-Week, Randomized, Double-Blind, Placebo-Controlled, Systemic, Gene-Delivery Clinical Trial for Duchenne Muscular Dystrophy Using SRP-9001 With a 96-Week Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarepta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sarepta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of exogenous gene transfer
      in DMD patients by measuring biological and clinical endpoints in two parts: a 48-week
      randomized, double-blinded, placebo-controlled period (Part 1), and a 96-week, double-blinded
      extension period (Part 2).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 22, 2018</start_date>
  <completion_date type="Anticipated">October 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Week 144</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to Week 144</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Quantity of Microdystrophin Protein Expression Measured by Western Blot</measure>
    <time_frame>Baseline up to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in North Star Ambulatory Assessment (NSAA) Total Score</measure>
    <time_frame>Baseline up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Time to Rise From the Floor and Ascend 4 Steps</measure>
    <time_frame>Baseline up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Time of 10 Meter and 100 Meter Timed Test</measure>
    <time_frame>Baseline up to Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Muscular Dystrophy, Duchenne</condition>
  <arm_group>
    <arm_group_label>SRP-9001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV infusion of SRP-9001.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo IV infusion 10 mL/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>SRP-9001</intervention_name>
    <description>Single IV infusion of SRP-9001</description>
    <arm_group_label>SRP-9001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single IV infusion of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established clinical diagnosis of DMD and documented dystrophin gene mutation of DMD
             phenotype.

          -  Indication of symptomatic muscular dystrophy by protocol-specified criteria.

          -  Ability to cooperate with motor assessment testing.

          -  Stable dose equivalent of oral corticosteroids for at least 12 weeks.

        Exclusion Criteria:

          -  Impaired cardiovascular function on ECHO.

          -  Prior or ongoing medical condition on physical examination, ECG, or laboratory
             findings that could adversely affect subject safety, compromise completion of
             follow-up, or impair assessment of study results.

          -  Exposure to another investigational drug or exon skipping medication within months.

          -  Exposure to an investigational or commercial gene therapy product.

          -  Abnormal liver or renal function by protocol-specified criteria

        Other inclusion/exclusion criteria apply.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sarepta Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 6, 2018</study_first_submitted>
  <study_first_submitted_qc>December 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2018</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne Muscular Dystrophy</keyword>
  <keyword>Gene-Delivery</keyword>
  <keyword>DMD</keyword>
  <keyword>Ambulatory</keyword>
  <keyword>Pediatric</keyword>
  <keyword>North Star Ambulatory Assessment (NSAA)</keyword>
  <keyword>Percent Dystrophin Positive Fibers (PDPF)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

